PCN132 Cost-Effectiveness Analysis of RE-Treatment with 177lu-Dotatate Versus NO RE-Treatment with 177lu-Dotatate in Patients with Progressive Midgut Neuroendocrine Tumors

Abstract

Authors

O. Leeuwenkamp R. Mahon M.K. Singh A. Khare

Full Text Cite This Article
Back to Volume 23, Supplemental S2
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×